Seelos Therapeutics Announces Participation Of Acadia Healthcare In The Registration Directed Study Of SLS-002 (Intranasal Racemic Ketamine) For Acute Suicidal Ideation And Behavior In Patients With Major Depressive Disorder
NEW YORK, Sept. 13, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
